Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

Next Previous
Trial Profile

A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Choroidal neovascularisation; Wet age-related macular degeneration
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms CANDELA
  • Sponsors Regeneron Pharmaceuticals

Most Recent Events

  • 02 Feb 2026 According to a Regeneron Pharmaceuticals Inc media release, the data from the trial will be presented at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026.
  • 28 Apr 2025 According to Regeneron Pharmaceuticals media release, data from this trial will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
  • 29 Apr 2024 According to a Bayer media release, the Pooled safety analysis of the CANDELA, PHOTON, and PULSAR trials will be presented at the the Annual Meeting of The Association for Research in Vision and Ophthalmology (arvo.org), in Seattle, Washington, 5-9 May 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top